{"protocolSection":{"identificationModule":{"nctId":"NCT04611893","orgStudyIdInfo":{"id":"Crec 2020.376"},"organization":{"fullName":"Chinese University of Hong Kong","class":"OTHER"},"briefTitle":"Monitoring of NOAC Therapy: Standardizing Reference Intervals","officialTitle":"Monitoring of NOAC Therapy: Standardizing Reference Intervals"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-11-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-08-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-08-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-10-27","studyFirstSubmitQcDate":"2020-10-27","studyFirstPostDateStruct":{"date":"2020-11-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-17","lastUpdatePostDateStruct":{"date":"2024-01-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Dr. IP Yiu Ming Bonaventure","investigatorTitle":"Specialist Resident","investigatorAffiliation":"Chinese University of Hong Kong"},"leadSponsor":{"name":"Chinese University of Hong Kong","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.","detailedDescription":"360 patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited. After the informed consent, the patient will be needed for blood taking before and 2 hours after the medication (NOAC). The patient's demographic data and medical history will also be retreived from Central Medical Syetem too."},"conditionsModule":{"conditions":["Ischemic Stroke","Stroke, Acute","Stroke Syndrome","Ischemic"],"keywords":["stroke","ischemic stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"Blood tests for haemoglobin level, platelet count, activated partial thromboplastin time (aPTT), prothrombin time (PT), international normalized ratio (INR), creatinine clearance (by Cockcroft-Gault formula), alanine aminotransferase, alkaline phosphatase, bilirubin, modified thrombin time (dabigatran users), factor-Xa assay (for apixaban, rivaroxaban users) will be performed at the same time as blood taking for NOAC levels."},"enrollmentInfo":{"count":360,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Ischemic stroke patient","description":"Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"NOAC level in blood","description":"The NOAC level in blood before and after the medication","timeFrame":"One week after the recruitment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Ethnic Chinese ONLY\n2. 18 years old or above\n3. Non-valvular atrial fibrillation\n4. Duration of NOAC use at least 3 months\n5. No changes in NOAC dosage or type within 3 months\n6. Creatinine Clearance (by Cockcroft-Gault formula) \\>/=30mL/min\n\nExclusion Criteria:\n\n1. Valvular atrial fibrillation or no atrial fibrillation\n2. Recent haemorrhage or ischemia within 1 year\n3. Active liver disease\n4. Abnormal baseline clotting profile\n5. Abnormal baseline thrombocytopenia or thrombocytosis\n6. Thromboembolic tendency other than atrial fibrillation (e.g. antiphospholipid syndrome, protein C, S, anti-thrombin III deficiency)\n7. Non-compliant patients, defined as missing any doses of NOAC in recent 1 month\n8. Anticoagulation for disorders other than AF\n9. Pregnancy","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Yiu Ming Bonaventure IP, MRCP","role":"CONTACT","phone":"852-35053856","email":"iym984@ha.org.hk"}],"overallOfficials":[{"name":"Yiu Ming Bonaventure IP, MRCP","affiliation":"Chinese University of Hong Kong","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Chinese University of Hong Kong","status":"RECRUITING","city":"Hong Kong","country":"Hong Kong","contacts":[{"name":"Yiu Ming Bonaventure IP, MRCP","role":"CONTACT","phone":"852-35053856","email":"iym984@ha.org.hk"}],"geoPoint":{"lat":22.27832,"lon":114.17469}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M16045","name":"Syndrome","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M288142","name":"Apixaban","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","relevance":"LOW"},{"id":"M490","name":"Dabigatran","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}